sorafenib has been researched along with thiophenes in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (thiophenes) | Trials (thiophenes) | Recent Studies (post-2010) (thiophenes) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 17,012 | 1,961 | 8,038 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bort, A; Díaz-Laviada, I; Mateos-Gómez, PA; Rodríguez-Henche, N; Sánchez, BG; Vara-Ciruelos, D | 1 |
| Chou, TC; Huang, YT; Lin, JD; Lin, SF; Wong, RJ; Yeh, CN | 1 |
2 other study(ies) available for sorafenib and thiophenes
| Article | Year |
|---|---|
Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers, Tumor; Biphenyl Compounds; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Pyrones; Sorafenib; Thiophenes; Time Factors; Xenograft Model Antitumor Assays | 2019 |
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Sorafenib; Thiophenes; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |